COVID-19 infection in patients with hematological cancer

Mina Ghorbani Mazar, Ali Nemati Siyahmazgi, Hossein Javid ©

COVID-19 infection in patients with hematological cancer

کد: G-67943

نویسندگان: Mina Ghorbani Mazar, Ali Nemati Siyahmazgi, Hossein Javid ©

زمان بندی: زمان بندی نشده!

برچسب: هماتولوژی

دانلود: دانلود پوستر

خلاصه مقاله:

Background and Aim

COVID-19 pandemic has been started by the SARS-CoV-2 Infection. There is limited information about the risk of COVID-19 infection in hematological cancer and their clinical signs and outcomes. An inflammatory process called “cytokine storm” which is a deadly complication of COVID-19 infection is mediated by hyper activation of effector T cells and excessive production of inflammatory cytokines like IL-6, IL-1, interferon-gamma, and TNF.

Methods

"blank"

Results

BCR-ABL tyrosine kinase inhibitors (TKI) therapy in CML patients shows a slight increase in infection risk, probably because of off-target kinases inhibition which have a role in immune cell function. Clinically significant immune suppression is not caused by chronic phase CML or BCR-ABL tyrosine kinase inhibitors. Furthermore, no evidence suggests that chronic phase CML patients are at a higher infection risk by SARS-CoV-2 in comparison to population. Therefore, stopping TKI treatment is not suggested when symptoms of SARS-CoV-2 exists since it may cause loss of response and CML relapse/progression. Studies showed that Abl1 tyrosine kinase adjusts budding or release of poxviruses and the Ebola virus. These results show that c-Abl1 kinase signaling pathways has vital role in viral departure and may be important in coronavirus replication. Imatinib may have anti-coronavirus activity in two points of life cycle of virus. In the early infection phase, it may block virion fusion with endosome and release into cytoplasm which inhibits viral entry and replication by Abl-mediated cytoskeletal rearrangement. In the latter phase, expression of Abl2 protein which activates SARS-CoV and MERS-CoV replication is inhibited by imatinib and dasatinib.

Conclusion

Ultimately, these studies imply a potential protective role of the TKIs in SARS-CoV-2 infection. Moreover, it should be mentioned that TKIs have previously been shown to be effective against other coronaviruses. Finally, Abl2 could be a is a novel host cell protein required for viral growth.

Keywords

SARS-CoV-2; COVID-19, CML; Hematological Cancer; BCR-ABL tyrosine kinase

دیدگاه ها (0)

تاکنون دیدگاهی منتشر نشده است. شما اولین نفر باشید!

ارسال یک دیدگاه

ارسال دیدگاه توسط مدیریت بسته شده است.